{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T16:23:45Z","timestamp":1790871825137,"version":"4.1.0"},"reference-count":39,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2024,5,28]],"date-time":"2024-05-28T00:00:00Z","timestamp":1716854400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>(1) Background: Geriatric patients are at high risk of complications of Coronavirus disease-2019 (COVID-19) and are good candidates for antiviral drugs. (2) Methods: A retrospective study of electronic health records (EHRs) aiming to describe antiviral (nirmatrelvir and ritonavir (nirmatrelvir\/r) or remdesivir) use, drug\u2013drug interactions (DDIs) and adverse drug reactions (ADRs) in elderly patients (75 and over), hospitalized with mild-to-moderate COVID-19 between July 2022 and June 2023. (3) Results: Out of 491 patients (mean age: 86.9 years), 180 (36.7%) received nirmatrelvir\/r, 78 (15.9%) received remdesivir, and 233 (47.4%) received no antiviral therapy. No association was found between the choice of antiviral and the demographic or medical data. No serious ADR was observed. Nirmatrelvir\/r dosage adjustment was inadequate in 65% of patients with renal impairment. In total, 128 patients (71%) on nirmatrelvir\/r had potential pharmacokinetic DDIs, with 43 resulting in a possibly related ADR. In the remdesivir group, pharmacodynamic DDIs were more frequent, with QTc prolongation risk in 56 patients (72%). Only 20 patients underwent follow-up ECG, revealing QTc prolongation in 4. (4) Conclusions: There is an underutilization of antivirals despite their justified indications. Nirmatrelvir\/r dosage was rarely adjusted to renal function. Dose adjustments and closer monitoring are needed due to the high risk of drug interactions.<\/jats:p>","DOI":"10.3390\/v16060864","type":"journal-article","created":{"date-parts":[[2024,5,28]],"date-time":"2024-05-28T07:38:39Z","timestamp":1716881919000},"page":"864","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Antiviral Use in Mild-to-Moderate SARS-CoV-2 Infections during the Omicron Wave in Geriatric Patients"],"prefix":"10.3390","volume":"16","author":[{"given":"Nadia","family":"Exquis","sequence":"first","affiliation":[{"name":"Division of Clinical Pharmacology and Toxicology, Department of Anesthesiology, Pharmacology, Intensive Care, and Emergency Medicine, Geneva University Hospitals, 1205 Geneva, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Dionisi","sequence":"additional","affiliation":[{"name":"Division of Clinical Pharmacology and Toxicology, Department of Anesthesiology, Pharmacology, Intensive Care, and Emergency Medicine, Geneva University Hospitals, 1205 Geneva, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline Flora","family":"Samer","sequence":"additional","affiliation":[{"name":"Division of Clinical Pharmacology and Toxicology, Department of Anesthesiology, Pharmacology, Intensive Care, and Emergency Medicine, Geneva University Hospitals, 1205 Geneva, Switzerland"},{"name":"Faculty of Medicine, University of Geneva, 1206 Geneva, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Rollason","sequence":"additional","affiliation":[{"name":"Division of Clinical Pharmacology and Toxicology, Department of Anesthesiology, Pharmacology, Intensive Care, and Emergency Medicine, Geneva University Hospitals, 1205 Geneva, Switzerland"},{"name":"Faculty of Medicine, University of Geneva, 1206 Geneva, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Curtin","sequence":"additional","affiliation":[{"name":"Division of Clinical Pharmacology and Toxicology, Department of Anesthesiology, Pharmacology, Intensive Care, and Emergency Medicine, Geneva University Hospitals, 1205 Geneva, Switzerland"},{"name":"Faculty of Medicine, University of Geneva, 1206 Geneva, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dina","family":"Zekry","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Geneva, 1206 Geneva, Switzerland"},{"name":"Division of Internal Medicine for the Aged, Department of Rehabilitation and Geriatrics, Geneva University Hospitals, 1205 Geneva, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0235-5046","authenticated-orcid":false,"given":"Christophe","family":"Graf","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Geneva, 1206 Geneva, Switzerland"},{"name":"Division of Geriatrics and Rehabilitation, Department of Rehabilitation and Geriatrics, Geneva University Hospitals, 1205 Geneva, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virgnie","family":"Prendki","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Geneva, 1206 Geneva, Switzerland"},{"name":"Division of Internal Medicine for the Aged, Department of Rehabilitation and Geriatrics, Geneva University Hospitals, 1205 Geneva, Switzerland"},{"name":"Division of Infectious Disease, Geneva University Hospitals, 1205 Geneva, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8472-7714","authenticated-orcid":false,"given":"Kuntheavy","family":"Ing Lorenzini","sequence":"additional","affiliation":[{"name":"Division of Clinical Pharmacology and Toxicology, Department of Anesthesiology, Pharmacology, Intensive Care, and Emergency Medicine, Geneva University Hospitals, 1205 Geneva, Switzerland"},{"name":"Faculty of Medicine, University of Geneva, 1206 Geneva, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,5,28]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1111\/all.14657","article-title":"Risk Factors for Severe and Critically Ill COVID-19 Patients: A Review","volume":"76","author":"Gao","year":"2021","journal-title":"Allergy"},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Alves, V.P., Casemiro, F.G., de Araujo, B.G., Lima, M.A.d.S., Oliveira, R.S.d., Fernandes, F.T.d.S., Gomes, A.V.C., and Gregori, D. (2021). Factors Associated with Mortality among Elderly People in the COVID-19 Pandemic (SARS-CoV-2): A Systematic Review and Meta-Analysis. Int. J. Environ. Res. Public Health, 18.","DOI":"10.20944\/preprints202102.0319.v1"},{"key":"ref_3","unstructured":"(2023, May 05). Coronavirus: Morts par \u00e2ge en France 2022. Available online: https:\/\/fr.statista.com\/statistiques\/1104103\/victimes-coronavirus-age-france\/."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1016\/j.jamda.2020.09.014","article-title":"Predictors of In-Hospital Mortality in Older Patients with COVID-19: The COVIDAge Study","volume":"21","author":"Mendes","year":"2020","journal-title":"J. Am. Med. Dir. Assoc."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Fericean, R.M., Oancea, C., Reddyreddy, A.R., Rosca, O., Bratosin, F., Bloanca, V., Citu, C., Alambaram, S., Vasamsetti, N.G., and Dumitru, C. (2023). Outcomes of Elderly Patients Hospitalized with the SARS-CoV-2 Omicron B.1.1.529 Variant: A Systematic Review. Int. J. Environ. Res. Public Health, 20.","DOI":"10.3390\/ijerph20032150"},{"key":"ref_6","unstructured":"National Institutes of Health (2023). COVID-19 Treatment Guidelines Panel (NIH) Coronavirus Disease 2019 (COVID-19) Treatment Guidelines."},{"key":"ref_7","unstructured":"Soci\u00e9t\u00e9 Suisse d\u2019Infectiologie (SSI) (2023). Traitement Pr\u00e9coce et Prophylaxie du COVID-19: Recommandations de la Soci\u00e9t\u00e9 Suisse d\u2019Infectiologie (SSI), Soci\u00e9t\u00e9 Suisse d\u2019Infectiologie (SSI)."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"m3379","DOI":"10.1136\/bmj.m3379","article-title":"A Living WHO Guideline on Drugs for Covid-19","volume":"370","author":"Agarwal","year":"2020","journal-title":"BMJ"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1056\/NEJMoa2118542","article-title":"Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19","volume":"386","author":"Hammond","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_10","unstructured":"Aleem, A., and Kothadia, J.P. (2023). StatPearls, StatPearls Publishing."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1056\/NEJMoa2116846","article-title":"Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients","volume":"386","author":"Gottlieb","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1002\/cpt.1434","article-title":"Pharmacodynamic Drug-Drug Interactions","volume":"105","author":"Niu","year":"2019","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1002\/cpt.2646","article-title":"Recommendations for the Management of Drug-Drug Interactions Between the COVID-19 Antiviral Nirmatrelvir\/Ritonavir (Paxlovid) and Comedications","volume":"112","author":"Marzolini","year":"2022","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"n1585","DOI":"10.1136\/bmj.n1585","article-title":"Optimizing Therapy to Prevent Avoidable Hospital Admissions in Multimorbid Older Adults (OPERAM): Cluster Randomised Controlled Trial","volume":"374","author":"Blum","year":"2021","journal-title":"BMJ"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1001\/archinternmed.2011.152","article-title":"Geriatric Drug Evaluation: Where Are We Now and Where Should We Be in the Future?","volume":"171","author":"Cho","year":"2011","journal-title":"Arch. Intern. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1007\/s10157-020-01996-4","article-title":"Hypokalemia in Patients with COVID-19","volume":"25","author":"Alfano","year":"2021","journal-title":"Clin. Exp. Nephrol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1111\/cts.12882","article-title":"Risk Assessment of Drug-Induced Long QT Syndrome for Some COVID-19 Repurposed Drugs","volume":"14","author":"Michaud","year":"2021","journal-title":"Clin. Transl. Sci."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"e102","DOI":"10.1016\/S1473-3099(21)00703-9","article-title":"WHO Clinical Case Definition Working Group on Post-COVID-19 Condition A Clinical Case Definition of Post-COVID-19 Condition by a Delphi Consensus","volume":"22","author":"Soriano","year":"2022","journal-title":"Lancet Infect. Dis."},{"key":"ref_19","unstructured":"World Health Organization (2024, February 28). Clinical Management of COVID-19\u2014Living Guideline.Pdf. Available online: https:\/\/iris.who.int\/bitstream\/handle\/10665\/372288\/WHO-2019-nCoV-clinical-2023.2-eng.pdf?sequence=1."},{"key":"ref_20","unstructured":"World Health Organization (2002). Safety of Medicines\u2014A Guide to Detecting and Reporting Adverse Drug Reactions, World Health Organization."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"10","DOI":"10.3109\/09638289509166622","article-title":"The Functional Independence Measure: A Comparative Validity and Reliability Study","volume":"17","author":"Kidd","year":"1995","journal-title":"Disabil. Rehabil."},{"key":"ref_22","unstructured":"Mendiratta, P., Schoo, C., and Latif, R. (2023). StatPearls, StatPearls Publishing."},{"key":"ref_23","unstructured":"Monegro, A.F., Muppidi, V., and Regunath, H. (2023). StatPearls, StatPearls Publishing."},{"key":"ref_24","unstructured":"(2023, November 30). Liverpool COVID-19 Interactions. Available online: https:\/\/www.covid19-druginteractions.org\/."},{"key":"ref_25","unstructured":"European Medicines Agency (2022). Paxlovid: EPAR\u2014Product Information: Summary of Product Characteristics, European Medicines Agency."},{"key":"ref_26","unstructured":"Office F\u00e9d\u00e9ral de la Statistique, O. (2023, November 23). Sant\u00e9 des Personnes \u00e2g\u00e9es. Available online: https:\/\/www.bfs.admin.ch\/bfs\/fr\/home\/statistiken\/gesundheit\/gesundheitszustand\/alter.html."},{"key":"ref_27","first-page":"547","article-title":"Efficacy and Safety of Oral Antivirals in Individuals Aged 80 Years or Older with Mild-to-Moderate COVID-19: Preliminary Report from an Italian Prescriber Center","volume":"30","author":"Bruno","year":"2022","journal-title":"Infez. Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1093\/infdis\/jiad324","article-title":"Real-World Effectiveness of Molnupiravir and Nirmatrelvir\/Ritonavir as Treatments for COVID-19 in Patients at High Risk","volume":"228","author":"Paraskevis","year":"2023","journal-title":"J. Infect. Dis."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Ramos-Rincon, J.-M., L\u00f3pez-Carmona, M.-D., Cobos-Palacios, L., L\u00f3pez-Sampalo, A., Rubio-Rivas, M., Mart\u00edn-Escalante, M.-D., de-Cossio-Tejido, S., Taboada-Mart\u00ednez, M.-L., Mui\u00f1o-Miguez, A., and Areses-Manrique, M. (2022). Remdesivir in Very Old Patients (\u226580 Years) Hospitalized with COVID-19: Real World Data from the SEMI-COVID-19 Registry. J. Clin. Med., 11.","DOI":"10.3390\/jcm11133769"},{"key":"ref_30","unstructured":"Office F\u00e9d\u00e9ral de la Sant\u00e9 Publique, O. (2023, November 23). COVID-\u206019 Suisse|Coronavirus|Dashboard. Available online: https:\/\/www.covid19.admin.ch\/fr\/vaccination\/persons?geoView=table&geo=CHFL&demoSum=total&ageRanges=70-79,80%2B."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1080\/13696998.2023.2281882","article-title":"The Impact of Vaccination and Outpatient Treatment on the Economic Burden of Covid-19 in the United States Omicron Era: A Systematic Literature Review","volume":"26","author":"Pierre","year":"2023","journal-title":"J. Med. Econ."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1001\/jamainternmed.2023.0743","article-title":"Association of Treatment With Nirmatrelvir and the Risk of Post-COVID-19 Condition","volume":"183","author":"Xie","year":"2023","journal-title":"JAMA Intern. Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.ejim.2023.09.025","article-title":"Cost-Effectiveness Analysis of Ritonavir Boosted Nirmatrelvir for Adult Outpatients with Mild to Moderate COVID-19 in a European Health System","volume":"118","author":"Ibarra","year":"2023","journal-title":"Eur. J. Intern. Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"105659","DOI":"10.1016\/j.antiviral.2023.105659","article-title":"Paxlovid for Hospitalized COVID-19 Patients with Chronic Kidney Disease","volume":"216","author":"Cai","year":"2023","journal-title":"Antivir. Res."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"622862","DOI":"10.3389\/fphar.2020.622862","article-title":"Identifying and Characterizing Serious Adverse Drug Reactions Associated With Drug-Drug Interactions in a Spontaneous Reporting Database","volume":"11","author":"Magro","year":"2020","journal-title":"Front. Pharmacol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"310","DOI":"10.2174\/138920008784220664","article-title":"Drugs Behave as Substrates, Inhibitors and Inducers of Human Cytochrome P450 3A4","volume":"9","author":"Zhou","year":"2008","journal-title":"Curr. Drug Metab."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Woo, S.A., Cragg, A., Wickham, M.E., Peddie, D., Balka, E., Scheuermeyer, F., Villanyi, D., and Hohl, C.M. (2018). Methods for Evaluating Adverse Drug Event Preventability in Emergency Department Patients. BMC Med. Res. Methodol., 18.","DOI":"10.1186\/s12874-018-0617-4"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"995","DOI":"10.2165\/11538280-000000000-00000","article-title":"Preventability of Drug-Related Harms\u2014Part II: Proposed Criteria, Based on Frameworks That Classify Adverse Drug Reactions","volume":"33","author":"Aronson","year":"2010","journal-title":"Drug Saf."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Wolfe, D., Yazdi, F., Kanji, S., Burry, L., Beck, A., Butler, C., Esmaeilisaraji, L., Hamel, C., Hersi, M., and Skidmore, B. (2018). Incidence, Causes, and Consequences of Preventable Adverse Drug Reactions Occurring in Inpatients: A Systematic Review of Systematic Reviews. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0205426"}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/16\/6\/864\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:49:30Z","timestamp":1760107770000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/16\/6\/864"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,28]]},"references-count":39,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2024,6]]}},"alternative-id":["v16060864"],"URL":"https:\/\/doi.org\/10.3390\/v16060864","relation":{},"ISSN":["1999-4915"],"issn-type":[{"value":"1999-4915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,28]]}}}